ISRCTN27750123已完成未知
Efficacy and tolerability of ziprasidone versus clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: a randomised study
niversity of Cologne (Germany)0 个研究点目标入组 30 人开始时间: 2006年1月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
2014 Results article in https://pubmed.ncbi.nlm.nih.gov/24628830/ (added 01/09/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with schizophrenia, schizophreniform or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (295.xx) and International Statistical Classification of Diseases and Related Health Problems - tenth revision (ICD-10) (F20, F23.2, F25) as well as cannabis abuse or dependence according to DSM-IV (305.20, 304.30) and ICD-10 (F12.1, 12.2)
- •2. Capable of giving written informed consent
排除标准
- •1. Other relevant neuropsychiatric disorders
- •2. Prominent (acute) positive symptoms at the timepoint of inclusion
- •3. Previous treatments with ziprasidone or clozapine with significant side effects
- •4. No availability of a family member or significant other for the collateral interviews of the follow-up evaluation
- •5. No compliance with the requirements of the study/lack of or questionable capability of giving informed consent
研究者
相似试验
进行中（未招募）
1 期
Study to compare the efficacy of ziprasidone (Zeldox) and aripiprazole (Abilify) on cognitive functioning and quality of sleep in the treatment of schizophrenic patientsSchizophreniaEUCTR2005-004501-28-DEDepartment of Psychiatry, Ludwig-Maximilians-University Munich60
进行中（未招募）
不适用
Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study - Ziprasidone vs. Clozapine for schizophrenia ans cannabis use disorderPatients with schizophrenia and cannabis abuse/dependency will be randomized to ziprasidone or clozapine treatment. Dose of medication and frequency of administration will be flexible and adjustable depending on clinical requirements. Duration of therapeutic trial:12 monthsEUCTR2005-003156-35-DEDepartment of Psychiatry and Psychotherapy (Cologne)50
已完成
3 期
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic PatientsPsychotic DisordersSchizophreniaSchizoaffective DisorderNCT00159770Pfizer's Upjohn has merged with Mylan to form Viatris Inc.290
已完成
2 期
Ziprasidone for Severe Conduct and Other Disruptive Behavior DisordersConduct DisorderOppositional Defiant DisorderNCT00676429University Hospital Freiburg51
已完成
4 期
Effectiveness of Ziprasidone for Patients With SchizophreniaSchizophreniaSchizoaffective DisorderNCT01198353Soonchunhyang University Hospital67